Jared Gollob

Jared Gollob

Company: Kymera Therapeutics

Job title: Chief Medical Officer

Seminars:

Panel Discussion: Demonstrating Degrader Efficacy 4:25 pm

• What is the challenge behind demonstrating degrader efficacy? • What methods are currently followed to overcome the challenge of showing degrader targeting to the protein of interest? • Establishing correlation between ubiquitination and target degradation, in vitro and in cell system remains a challenge. Tackling this problem will be key to establishing structure-activity relationship…Read more

day: Agenda: TPD: Emerging Disease Applications Beyond Oncology

Phase 1 Trial of IRAK4 Degrader KT-474 in Healthy Volunteers & Patients with Atopic Dermatitis & Hidradenitis Suppurativa 3:35 pm

• Interim data from Healthy Volunteer SAD and MAD portions of the trial • Data to include safety, PK, and PD establishing proof-of-mechanism and proof-of-biologyRead more

day: Agenda: TPD: Emerging Disease Applications Beyond Oncology

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.